Diabetes surge offset by partnership drag; margins intact but outlook hedged

H1 diabetes +17% growth; Q2 domestic +8%, diabetes subset higher; overall revenue +7.7% YoY

Specific sub-segment claim; not contradicted; described as discipline, execution, new state accounts

Confirmed; acknowledged as below expectation; management expects 2027 recovery, not year-end 2026

Reported PAT ₹83.5 Cr; PBT growth claim consistent with +20.1% PAT YoY; margin improvement evident

MD explicitly avoids commitment: 'I don't know whether it's 14%, 15%, or 10%'; hedged outlook

17% H1 diabetes growth exceeds prior 'continued strong growth' expectation; public sector 70% growth concrete; validates strategy focus.

Prior guidance implied stabilization by year-end 2026; Rachid now says 'maybe 2026, definitely 2027' — 6-12 month delay; structural issues, not one-offs.

Novo Nordisk Awiqli (once-weekly insulin) launched; management says 'patient profiles differ' and 'too early to comment'; specific risk not previously disclosed.

Q1 2025 had safety stock build and sales returns (one-offs); Q2 2026 showing 2% apple-to-apple; competition aggressive; we expect 2027 catch-up. Partners reorganizing teams, strict steering committee follow-up. It's strategic and important.

Don't know if 14%, 15%, or 10%, but promise continued support. Large TAM (100M underdiagnosed). GLP-1 won't impact insulin; insulin is complementary. No new products; evaluating devices, AI platforms.

Welcome innovation. Patient profiles differ (once-weekly vs once-daily very different). Market is big. Share of voice will help. Too early to comment on major impact. Wait for a quarter to see momentum.

Insulin gold standard of care; complementary to GLP-1. Analog segment double-digit sustained. Export offsetting Australia with France, Italy, Turkey, Russia. Goa as specialized site. South Africa tenders pending.

Not in strategy today. Discussed in Board but no commitment. Other capital priorities.

H1 diabetes +17% validates 'strong growth' prior guidance; public sector 70% concrete; but MD won't commit to 14% going forward; hedged.

Q2 margin 27%; opex discipline evident (-5% Q2, -15% H1); sustained focus on ROI-positive investments only; margin expansion trajectory clear.

Emcure and Cipla portfolio (CV, CNS, Amaryl) growing only 2% in Q2, below industry growth. Analysts flagged multi-quarter anemia. Management deferred catch-up to 2027, not year-end 2026.

Export revenue -2% YoY; Australia experiencing heavy competition on mature products. Offsetting strategy relies on new markets (France, Italy, Turkey, Russia) with uncertain traction.

Novo Nordisk launched Awiqli (once-weekly long-acting insulin). Management claims patient profiles differ (once-weekly vs once-daily) but acknowledges new initiates may prefer once-weekly; calls impact 'too early to comment.'

Diabetes showed 14% Q2 growth; analysts asked if sustainable for H2. MD explicitly refused to commit: 'I don't know whether it's 14%, 15%, or 10%, but yes, the promise what we have with ourselves...is that we'll continue doing what we can do.'

Management claims Soliqua (+16% growth) benefits from GLP-1 share of voice, but framed as opportunity. Underlying risk: GLP-1 biosimilar entry could erode pricing of Soliqua or shift mix.